Get started
Author

Teeru Bihani

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
2017 · Hitisha K. Patel, Teeru Bihani · Pharmacology & Therapeutics · 536
PDF
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
2017 · Teeru Bihani, Hitisha K. Patel, et al. · Clinical Cancer Research · 171
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
2015 · Sylvie M. Guichard, Jon Curwen, et al. · Molecular Cancer Therapeutics · 133
PDF
Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells
2005 · K Zu, T Bihani, et al. · Oncogene · 108
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
2019 · Hitisha K. Patel, Nianjun Tao, et al. · Breast Cancer Research · 82
PDF
The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY
2012 · Scott A. Ezell, Christos Polytarchou, et al. · Proceedings of the National Academy of Sciences · 81
Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary Epithelium
2012 · Nelson E. Brown, Rinath Jeselsohn, et al. · Cancer Research · 77
EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer
2019 · Aditya Bardia, Philippe Aftimos, et al. · Future Oncology · 71
PDF
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
2014 · Teeru Bihani, Scott A. Ezell, et al. · Oncotarget · 62
PDF
Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
2014 · Scott A. Ezell, Michele Mayo, et al. · Oncotarget · 57
PDF
Differential Oncogenic Ras Signaling and Senescence in Tumor Cells
2004 · Teeru Bihani, Douglas X. Mason, et al. · Cell Cycle · 41
PDF
Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
2016 · Scott A. Ezell, Suping Wang, et al. · Oncotarget · 33
PDF
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
2016 · Brendon Ladd, Anne Marie Mazzola, et al. · Oncotarget · 31
PDF
Dissecting the Senescence-like Program in Tumor Cells Activated by Ras Signaling
2006 · Teeru Bihani, Agustin Chicas, et al. · Journal of Biological Chemistry · 29
PDF
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
2022 · Sunil Pancholi, Nikiana Simigdala, et al. · npj Breast Cancer · 25
PDF
Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
2020 · Virginia Kaklamani, Aditya Bardia, et al. · Cancer Research · 13
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).
2024 · Niven Mehra, Jens Voortman, et al. · Journal of Clinical Oncology · 12
Novel Expression of CST1 as Candidate Senescence Marker
2011 · Daniel Keppler, Jun Zhang, et al. · The Journals of Gerontology Series A · 10
Abstract P6-20-08: Anti-tumor activity of elacestrant (RAD1901) in models harboring ESR1 mutations resistant to standard of care therapies
2019 · H Patel, N Tao, et al. · Cancer Research · 9
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
2023 · Taronish D. Dubash, Aditya Bardia, et al. · Breast Cancer Research and Treatment · 7
PDF
Phase 1/2 dose escalation study of NUV-422, a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, in recurrent or refractory (r/r) high-grade gliomas (HGG) and solid tumors.
2022 · Patrick Y. Wen, Jordi Rodon Ahnert, et al. · Journal of Clinical Oncology · 4
Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutations
2020 · Taronish Dorab Dubash, Aditya Bardia, et al. · Cancer Research · 2
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.
2019 · Aditya Bardia, Philippe Georges Aftimos, et al. · Journal of Clinical Oncology · 2
Abstract P4-13-03: Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
2019 · H Patel, N Tao, et al. · Cancer Research · 2
Abstract P4-04-17: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model
2018 · H Arlt, F Garner, et al. · Cancer Research · 2
Works count: 62
Citation count: 1,607
H-index: 15
I10-index: 18
Year
Topic
Type